Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Read More >>Left sniffling and sneezing after a whirlwind 4 days at…
Approximately one in 31 hospital patients has at least one…
Anyone doubting the prevalence of workplace violence (WPV) in the…